These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38103759)

  • 1. METTL3/IGF2BP3-regulated m6A modification of HYOU1 confers doxorubicin resistance in breast cancer.
    Zhou S; Sheng L; Zhang L; Zhang J; Wang L
    Biochim Biophys Acta Gen Subj; 2024 Mar; 1868(3):130542. PubMed ID: 38103759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. METTL3-mediated m
    Zhou Z; Cao Y; Yang Y; Wang S; Chen F
    Epigenetics; 2023 Dec; 18(1):2217033. PubMed ID: 37243702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
    Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
    Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA.
    Fu W; Liu L; Tong S
    Thorac Cancer; 2024 Jun; 15(17):1357-1368. PubMed ID: 38709912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
    Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. METTL3/IGF2BP2 axis affects the progression of colorectal cancer by regulating m6A modification of STAG3.
    Yi J; Peng F; Zhao J; Gong X
    Sci Rep; 2023 Oct; 13(1):17292. PubMed ID: 37828232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis.
    Zhao C; Ling X; Xia Y; Yan B; Guan Q
    Cancer Cell Int; 2021 Aug; 21(1):441. PubMed ID: 34419065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of m6A methyltransferase METTL3 -mediated MALAT1/E2F1/AGR2 axis on adriamycin resistance in breast cancer.
    Li S; Jiang F; Chen F; Deng Y; Pan X
    J Biochem Mol Toxicol; 2022 Jan; 36(1):e22922. PubMed ID: 34964205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. METTL3-mediated m6A modification of EPPK1 to promote the development of esophageal cancer through regulating the PI3K/AKT pathway.
    Jia J; Yu L
    Environ Toxicol; 2024 May; 39(5):2830-2841. PubMed ID: 38293837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. METTL3 Reduces Oxidative Stress-induced Apoptosis in Presbycusis by Regulating the N6-methyladenosine Level of SIRT1 mRNA.
    Wang E; Li Y; Li H; Liu Y; Ming R; Wei J; Du P; Li X; Zong S; Xiao H
    Neuroscience; 2023 Jun; 521():110-122. PubMed ID: 37087022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
    Meng QZ; Cong CH; Li XJ; Zhu F; Zhao X; Chen FW
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4328-4336. PubMed ID: 32373970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent.
    Wang X; Tian L; Li Y; Wang J; Yan B; Yang L; Li Q; Zhao R; Liu M; Wang P; Sun Y
    J Exp Clin Cancer Res; 2021 Feb; 40(1):80. PubMed ID: 33637103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF2BP3 mediates the mRNA degradation of NF1 to promote triple-negative breast cancer progression via an m6A-dependent manner.
    Zhang X; Shi L; Sun HD; Wang ZW; Xu F; Wei JF; Ding Q
    Clin Transl Med; 2023 Sep; 13(9):e1427. PubMed ID: 37743642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. METTL3 and STAT3 form a positive feedback loop to promote cell metastasis in hepatocellular carcinoma.
    Liu B; Cao J; Wu B; Hao K; Wang X; Chen X; Shen Z
    Cell Commun Signal; 2023 May; 21(1):121. PubMed ID: 37231451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer.
    Ouyang D; Hong T; Fu M; Li Y; Zeng L; Chen Q; He H; Wen Y; Cheng Y; Zhou M; Zou Q; Yi W
    Breast Cancer Res; 2023 Feb; 25(1):19. PubMed ID: 36765397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner.
    Pan X; Hong X; Li S; Meng P; Xiao F
    Exp Mol Med; 2021 Jan; 53(1):91-102. PubMed ID: 33420414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
    Ma Z; Li Q; Liu P; Dong W; Zuo Y
    Cell Biol Int; 2020 Dec; 44(12):2524-2531. PubMed ID: 32869897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma.
    Liu L; He J; Sun G; Huang N; Bian Z; Xu C; Zhang Y; Cui Z; Xu W; Sun F; Zhuang C; Man Q; Gu S
    Clin Transl Med; 2022 May; 12(5):e778. PubMed ID: 35522946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. METTL3-mediated m6A modification of SIRT1 mRNA inhibits progression of endometriosis by cellular senescence enhancing.
    Wang X; Wang J; Zhao X; Wu H; Li J; Cheng Y; Guo Q; Cao X; Liang T; Sun L; Zhang G
    J Transl Med; 2023 Jun; 21(1):407. PubMed ID: 37353804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. METTL3 Promotes Osteosarcoma Metastasis via an m6A-dependent Epigenetic Activity of CBX4.
    Huo XS; Lu D; Chen DG; Ye M; Wang XW; Shang FS
    Front Biosci (Landmark Ed); 2024 Mar; 29(3):120. PubMed ID: 38538251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.